TCM
KRYS icon

TimesSquare Capital Management’s Krystal Biotech KRYS Stock Holding History

TimesSquare Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.5M Sell
111,545
-797
-0.7% -$238K 0.61% 62
2026
Q1 		$29M Buy
112,342
+14,942
+15% +$3.98M 0.49% 78
2025
Q4 		$24M Sell
97,400
-21,114
-18% -$4.44M 0.36% 102
2025
Q3 		$20.9M Buy
118,514
+4,310
+4% +$645K 0.3% 116
2025
Q2 		$15.7M Sell
114,204
-27,979
-20% -$4.11M 0.23% 125
2025
Q1 		$25.6M Sell
142,183
-16,685
-11% -$2.81M 0.41% 87
2024
Q4 		$24.9M Buy
158,868
+44,646
+39% +$7.92M 0.36% 107
2024
Q3 		$20.8M Buy
114,222
+31,183
+38% +$6.01M 0.31% 115
2024
Q2 		$15.2M Sell
83,039
-14,122
-15% -$2.37M 0.24% 126
2024
Q1 		$17.3M Sell
97,161
-153,309
-61% -$21.3M 0.25% 130
2023
Q4 		$31.1M Buy
250,470
+127,435
+104% +$14.1M 0.46% 90
2023
Q3 		$14.3M Buy
+123,035
New +$15M 0.22% 132

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

TimesSquare Capital Management's KRYS Position: Q2 2026 in Review

TimesSquare Capital Management reduced its Krystal Biotech (KRYS) stake by 0.71% in Q2 2026, selling an estimated $238K and leaving 111,545 shares worth $41.5M. The position accounts for 0.61% of the portfolio, ranked #62.

TimesSquare Capital Management first reported a position in KRYS in Q3 2023 and has held it in 12 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • TimesSquare Capital Management held 111,545 shares of Krystal Biotech worth $41.5M as of Q2 2026.
  • TimesSquare Capital Management sold 797 Krystal Biotech shares in Q2 2026, an estimated $238K.
  • Krystal Biotech made up 0.61% of TimesSquare Capital Management's portfolio in Q2 2026, its #62 holding.
  • TimesSquare Capital Management first reported a position in Krystal Biotech in Q3 2023 and has held it in 12 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on TimesSquare Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.